Prudential Financial Inc. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 136,988 shares of the biopharmaceutical company’s stock after buying an additional 30,859 shares during the period. Prudential Financial Inc. owned 0.13% of Regeneron Pharmaceuticals worth $67,280,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. National Pension Service raised its position in Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares during the last quarter. Grandfield & Dodd LLC raised its position in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares during the last quarter. Princeton Capital Management Inc. raised its position in Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares during the last quarter. CIBC World Markets Inc. raised its position in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its position in Regeneron Pharmaceuticals by 3.4% in the first quarter. Oppenheimer & Co. Inc. now owns 5,808 shares of the biopharmaceutical company’s stock valued at $2,251,000 after buying an additional 189 shares during the last quarter. 67.96% of the stock is owned by institutional investors.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 477.80 on Monday. The stock has a market capitalization of $50.66 billion, a price-to-earnings ratio of 47.93 and a beta of 1.66. The firm’s 50 day moving average is $487.65 and its 200 day moving average is $435.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.82 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Prudential Financial Inc.” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2017/08/28/regeneron-pharmaceuticals-inc-regn-shares-bought-by-prudential-financial-inc.html.

REGN has been the subject of several recent research reports. Vetr lowered shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price objective for the company. in a research note on Monday, May 15th. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective for the company. in a research note on Tuesday, August 1st. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Credit Suisse Group lowered shares of Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price objective for the company. in a research note on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $495.59.

In other news, Chairman P Roy Vagelos sold 56,213 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $474.48, for a total transaction of $26,671,944.24. Following the completion of the sale, the chairman now owns 363,638 shares in the company, valued at $172,538,958.24. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Sanofi bought 166,415 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were purchased at an average price of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 131,790 shares of company stock valued at $62,940,303. 10.40% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.